Skip to main content

DIADEMA PARTNERS LP

Position in VKTX — Viking Therapeutics, Inc.

CIK 2026172 MORRISTOWN, NJ

Position in VKTX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$17,089,389
+$5,239,042 QoQ
Shares Held
525,181
+55.9% QoQ
Ownership
0.452%
of shares outstanding
% of Portfolio
7.63%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in VKTX Over Time

Shares Held

Position Value (USD)

Derivatives in VKTX

reported options exposure · as of Mar 31, 2026
CallValue
$21,450,368
CallShares
659,200
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

DIADEMA PARTNERS LP holds $176,357,038 across 73 Biotechnology names. VKTX ranks #1 (9.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VKTX
Viking Therapeutics, Inc.
This page
525,181 $17,089,389

All Filings in VKTX

Export CSV
10 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $21,450,368 659,200
2026-03-31 $17,089,389 525,181
2025-12-31 $24,235,502 688,900
2025-12-31 $11,850,347 336,849
2025-12-31 $11,141,506 316,700
2025-09-30 $10,646,028 405,100
2025-09-30 $5,090,146 193,689
2025-06-30 $5,232,902 197,468
2025-03-31 $2,514,522 104,121
2025-03-31 $1,207,500 50,000